Portfolio Highlights

• Plexxikon publishes PLX4032 Phase 1 data in the New England Journal of Medicine
  August 25, 2010
• Achillion Announces Private Placement of $50 Million
  August 18, 2010
• CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan in the treatment of acute migraine attacks
  June 9, 2010
• GE Healthcare forms strategic alliance with cardiovascular genomic diagnostic company, CardioDx
  May 13, 2010

Pappas Ventures News

• Raleigh News and Observer: "Legislators aid N.C. life sciences"
  July 16, 2010
• "The Business of Biotechnology"
  March, 2010
• New York Times Series: "A Roller Coaster Chase for a Cure"
  February 22, 2010

In the Spotlight

• Eric Linsley, Managing Partner
  Eric was named Managing Partner in 2009, and over the past 10 years has played a key role in many of our most successful exits, including the recent sale of FlowCardia to Bard Inc.
• Scott Weiner
  Senior Principal
  Promoted to Senior Principal earlier this year, Scott was part of the Pappas Ventures team that assisted Anthera (Nasdaq: ANTH) with its IPO in March of this year.

• CardioDx
  CardioDx, a pioneer in the field of cardiovascular genomic diagnostics, is Pappas Ventures' first investment in the field of personalized medicine.
• Afferent Pharmaceuticals
  Afferent, co-founded by Pappas Ventures in December 2009, is focused on developing first-in-class medicines to treat chronic pain.